null

null

null

null

null

null

null

null

null

Minimal debt; primarily equity-funded clinical-stage biotech with cash runway financed via equity raises and partnership milestones; near-zero leverage ratio.

Negligible direct interest rate sensitivity; no significant floating-rate debt. Higher rates increase cost of future equity capital raises, indirectly pressuring burn rate management.

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) GalNAc ligand chemistry synthesis concentrated in EU/UK specialty CMOs; 2) RNA oligonucleotide raw materials sourced from limited Asian API suppliers vulnerable to export controls.

Pre-revenue clinical stage; no meaningful international commercial revenue. Currency devaluation risk immaterial currently but USD/GBP mismatch affects UK-listed operating costs.

Headquartered London (GBP-denominated costs); R&D operations in Berlin (EUR); USD-denominated partnership revenues from AstraZeneca and Novo Nordisk create multi-currency mismatch.

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on single-source GalNAc-siRNA synthesis CMO partners; substitution of oligonucleotide manufacturers would require 12-18 months regulatory revalidation, representing critical lock-in.

Cloud disruption risk is low-moderate; bioinformatics and clinical data platforms could be migrated within 60-90 days. Core IP and wet-lab operations are not cloud-dependent.

Partnership/licensing biotech: primary model is out-licensing siRNA therapeutic assets to large pharma for milestones and royalties, not SaaS or direct cloud-dependent service delivery.

API coupling risk is low; no externally exposed commercial APIs. Internal bioinformatics pipelines have moderate switching cost but are not revenue-critical in the near term.

Standard equity security; revenue model is pharmaceutical licensing/milestones. No Howey Test risk — revenue derives from contractual pharma partnerships, not passive investment in a common enterprise.

Very High

Moderate GDPR exposure from clinical trial patient data in EU/UK; CCPA exposure minimal as no US consumer data collected commercially. Compliance infrastructure standard for EU clinical-stage biotech.

Low antitrust risk; pre-commercial niche rare disease/cardiometabolic RNA therapeutics. No dominant market position; operates in competitive space alongside Alnylam, Dicerna without monopoly concerns.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~100% transactional/milestone-based currently; revenues consist of non-recurring upfront license fees and R&D milestones from AstraZeneca and Novo Nordisk partnerships. No subscription revenue.

Out-licensing siRNA platform assets for upfront payments, development milestones, and backend royalties on net sales. Future royalty streams will become recurring upon partner commercialization.

Pricing set via negotiated pharma partnership deals; not market-tested at scale. Royalty rates (typically 5-12% net sales) are standard but Silence has limited pricing leverage as a smaller licensor.

Low-to-moderate; pricing power constrained by competitive siRNA licensors (Alnylam dominant). Differentiated GalNAc delivery chemistry provides modest premium but negotiating position vs. large pharma is limited.

61.5% Gross Margin (Premium (>60%))

No free-rider leakage risk; proprietary GalNAc-siRNA IP is patent-protected. Partnership 'churn' risk exists if AstraZeneca/Novo Nordisk terminate agreements — high concentration risk in two partners.

Revenue growth is sublinear to headcount; milestone/royalty revenue scales with partner execution, not Silence headcount. Doubling revenue requires minimal proportional headcount increase.

Near-zero marginal cost for milestone payments received; royalty revenue is effectively zero marginal cost. R&D pipeline expansion does require incremental headcount and CRO spend.

Not applicable; Silence Therapeutics does not operate a franchise network.

At 10x scale, unit economics improve dramatically as royalty revenue requires no incremental CAC. Platform deal economics hinge on partner sales force scale, not Silence's direct sales spend.

No meaningful network effects; biotech IP licensing model does not benefit from user-scale network dynamics. Value accrues from IP depth and clinical validation, not network size.

-67.4% Return on Assets (Negative equity)

Moderate-high resilience; large pharma partners (AstraZeneca, Novo Nordisk) have recession-resistant revenues. Milestone payments could slow if partners tighten R&D budgets in severe downturns.

Large global pharmaceutical companies (AstraZeneca, Novo Nordisk) seeking RNA therapeutic platform access for cardiometabolic and rare disease indications; ~2 active major partners.

Potential future partners: mid-to-large biopharma seeking validated GalNAc-siRNA liver-targeting capability. Academic/government collaborations are peripheral and non-revenue generating currently.

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

9.8% CapEx / Revenue (Moderate-CapEx)

0001479615

SLN